Meta-analysis of clarithromycin compared to other antibiotics for the treatment of lower respiratory tract infections;Metaanálisis de la claritromicina comparada con otros antimicrobianos en el tratamiento de las infecciones de vías respiratorias bajas

Revista Espanola de Quimioterapia

Volumn 16, Issue 4, 2003, Pages 403-411

  Gálvez Múgica, Ma Angeles ^a,b   Espinosa De Los Monteros, M J ^a   Gallego Sandin S ^a   Novalbos, J ^a   Abad Santos, F ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Bronchitis; Clarithromycin; Lower respiratory tract infections; Meta analysis; Pneumonia

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; ERYTHROMYCIN;

ABDOMINAL PAIN; ADVERSE DRUG REACTION; ANTIBIOTIC THERAPY; ARTICLE; BRONCHITIS; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG FORMULATION; DRUG SAFETY; DYSPEPSIA; HEADACHE; HUMAN; LOWER RESPIRATORY TRACT INFECTION; META ANALYSIS; NAUSEA; PATIENT COMPLIANCE; PNEUMONIA; RISK BENEFIT ANALYSIS; TASTE DISORDER;

ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; CLINICAL TRIALS; HUMANS; RESPIRATORY TRACT INFECTIONS;

EID: 0842343630     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. a ed. Masson, Barcelona 1997; 1123-1129.
2. Langtry, H.D., Brogden, R.N. Clarithromycin: A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients. Drugs 1997; 53: 973-1004.
3. Rodvold, K.A. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet 1999; 37: 385-398.
4. Peters, D.H., Clissold, S.P. Clarithromycin: A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992; 44: 117-164.
5. DerSimonian, R., Charette, L.J., McPeek, B., Mosteller, F. Reporting on methods in clinical trials. N Engl J Med 1982; 306: 1332-1337.
6. D'Agostino, R.B., Weintreaub, M. Meta-analysis: A method for synthesizing research. Clin Pharmacol Ther 1995; 58: 605-616.
7. Wettengel, R., Vetter, N., Waardenburg, F.A. Clarithromycin vs cefaclor for the treatment of mild to moderate acute bacterial bronchitis. J Antimicrob Chemother 1993; 31: 963-972.
8. Notario, G., Siepman, N., Devcich, K., Guay, D.R.P. Comparative safety and efficacy of clarithromycin and three oral cephalosporins in the treatment of outpatients with bacterial bronchitis. Curr Res Ther 1993; 54: 628-640.
9. Neu, H.C., Chick, T.W. Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections. Chest 1993; 104: 1393-1399.
10. Fong, I.W., Laforge, J., Dubois, J., Small, D., Grossman, R., Zakhari, R. The Canadian Bronchitis Study Group. Clarithromycin vs cefaclor in lower respiratory tract infections. Clin Invest Med 1995; 18: 131-138.
11. Spiritus, E.M., Chang, R.J., Zhang, J.X. y cols. Cost savings of clarithromycin compared with erythromycin or cefaclor in the treatment of lower respiratory tract infection: Results of a randomized, multicenter study. Am J Managed Care 1998; 4 (Suppl. 10): S562-S570.
12. Ziering, W., McElvaine, P. Randomized comparison of once-daily ceftibuten and twice daily clarithromycin in the treatment of acute exacerbation of chronic bronchitis. Infection 1998; 26: 68-75.
13. Gatchalian. A single blind randomized, phase III comparative study of claritrhomycin, cefaclor and amoxicillin/clavulanic acid suspensions in the treatment of patients with lower respiratory tract infections. ICMASK, Barcelona 1998.
14. Devcich, K. Comparison of clarithromycin and loracarbef in the treatment of secondary bacterial infections of acute bronchitis. ICMAS, 2000.
15. Guay, D.R.P., Siepman, N., Tanaka, S.K. y cols. Comparative safety and efficacy of clarithromycin and 3 oral caphalosporins in the treatment of outpatiens with bacterial bronchitis due to Haemophilus influenzae. Drug Invest 1993; 6: 33-41.
16. Spiritus, E.M. Clarithromycin in the treatment of bacterial exacerbations of chronic bronchitis in smokers. Curr Ther Res 1995; 56: 16-23.
17. Sappington, R.F. Jr., Fogarty, C., Nolen, T.M., Brandon, M.L. A multicenter study of cefprozil vs clarithromycin in the treatment of acute bacterial exacerbations of chronic bronchitis. Infect Med 1997; 14 (Suppl.): 61-68.
18. Genne, D., Siegrist, H.H., Humair, L., Janin Jaquat, B., de Torrente, A. Clarithromycin vs amoxicillin/clavulanic acid in the treatment of community acquired pneumonia. Eur J Clin Microbiol Infect Dis 1997; 16: 783-788.
19. Martinot, B., Heredia Budo, L., Estruch Riba, R. y cols. Safety and efficacy of clarithromycin once daily vs amoxicillin clavulanate in the treatment of acute exacerbation of chronic bronchitis. ICMASK, Barcelona 1998.
20. Gatchalian, S.R., Tiangco, B., Medalla, y cols. A single blind randomized, phase III comparative study of clarithromycin, cefaclor and amoxicillin/clavulanic acid suspensions in the treatment of patients with lower respiratory tract infections. ICMASK, Barcelona 1998.
21. Vincken, W., Martinot, J.B. A comparative study of the safety and efficacy of clarithromycin 500 mg and amoxicillin/clavulanic acid in the treatment of acute exacerbation of chronic bronchitis. ICMASK, Sevilla 2000.
22. Hutton. Cost effectiveness of once daily claritrhomycin compared to amoxicillin/clavulanic acid in the treatment of acute exacerbation of chronic bronchitis. ICMASK 2000.
23. Genne, D. A comparative analysis of clarithromycin IV and amoxicillin clavulanic acid IV in the treatment of community acquired pneumonia. ICMASK 1998; II-12.
24. Bradbury, F. Comparison of azithromycin vs clarithromycin in the treatment of patients with lower respiratory tract infection. J Antimicrob Chemother 1993: 31 (Suppl. E): 153-162.
25. Pozzi, E., Grossi, E., Pecori, A. Azithromycin vs clarithromycin in the treatment of acute exacerbations of chronic bronchitis. Curr Ther Res Clin Exp 1994; 55: 759-764.
26. Sternon, J., Leclerq, P., Knepper, C., Blot. K. Azithromycin compared with clarithromycin in the treatment of adult patients with acute purulent tracheobronchitis: A cost of illness study. J Int Med Res 1995; 23: 413-422.
27. Rizzato, G., Montemurro, L., Fraioli, P. y cols. Efficacy of a three day course of azithromycin in moderatly severe community acquired pneumonia. Eur Respir J 1995; 8: 398-402.
28. O'Doherty, B., Muller, O. Azithromycin Study Group. Randomized, multicentre study of the efficacy and tolerance of azithromycin vs clarithromycin in the treatment of adults with mild to moderate community acquired pneumonia. Eur J Clin Microbiol Infect Dis 1998; 17: 828-833.
29. Anderson, G., Esmonde, T.S., Coles, S., Macklin, J., Carnegie, C. A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia. J Antimicrob Chemother 1991; 27 (Suppl. A): 117-124.
30. Chien, S.M., Pichotta, P., Siepman, N., Chand, C.K., The Canada-Sweeden Clarithromycin-Pneumonia Study Group. Treatment of community-acquired pneumonia: A multicenter, double-blind, randomized study comparing clarithromycin with erithromycin. Chest 1993; 103: 697-701.
31. Block, S., Hedrick, J., Hammerschalg, M.R., Cassell, G.H., Craft, J.C. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community acquired pneumonia: Comparative efficacy and safety of clarithromycin vs erithromycin ethylsuccinate. Pediatr Infect Dis J 1995; 14: 471-477.
32. Spiritus, E.M., Chang, R.J., Zhang, J.X. y cols. Cost savings of clarithromycin compared with erythromycin or cefaclor in the treatment of lower respiratory tract infection: Results of a randomized, multicenter study. Am J Managed Care 1998; 4 (Suppl. 10): S562-S570.
33. Gotfried, M.H., Killian, A.D., Servi, R.J., Danziger, L.H., Rodvold, K.A. Cefuroxime plus oral clarithromycin or IV erythromycin for the treatment of community-acquired pneumonia in hospitalised patients. A pilot study. Clin Drug Invest 1997; 14: 23-34.
34. Vetter, N., Stamler, D., O'Neill, S. y cols. Clarithromycin vs combined cefuroxime and erythromycin in the treatment of hospitalised community-acquired pneumonia patients - Intravenous followed by oral therapy. Clin Drug Invest 1997; 14: 439-449.
35. Vetter, N. A comparative analysis of clarithromycin IV vs combined cefuroxime IV and erithromycin in the treatment of community-acquired pneumonia. ICMASK, Barcelona 1998.
36. Jang, T.N., Liu, C.Y., Wang, F.D., Yang, S.P., Fung, C.P. A randomized comparative study on the safety and efficacy of clarithromycin and erithromycin in treating community acquired pneumonia. Chung Hua I Hsueh Tsa Chih Taipei 1995; 55: 302-306.
37. Peters, D.H., Clissold, S.P. Clarithromycin: A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992; 44: 117-164.
38. Abad-Santos, F., Gálvez-Múgica, M.A., García, A.G. Farmacocinética, eficacia y seguridad de la claritromicina, en una dosis al día, para las infecciones respiratorias. Med Clin Monogr 2001; 2: 87-92.
39. Rodvold, K.A. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet 1999; 37: 385-398.